WO2020191270A1 - Stabilized formulations containing anti-il-33 antibodies - Google Patents

Stabilized formulations containing anti-il-33 antibodies Download PDF

Info

Publication number
WO2020191270A1
WO2020191270A1 PCT/US2020/023795 US2020023795W WO2020191270A1 WO 2020191270 A1 WO2020191270 A1 WO 2020191270A1 US 2020023795 W US2020023795 W US 2020023795W WO 2020191270 A1 WO2020191270 A1 WO 2020191270A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
stable liquid
antibody
liquid pharmaceutical
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/023795
Other languages
English (en)
French (fr)
Inventor
Qingyan HU
Dingjiang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL286024A priority Critical patent/IL286024B2/en
Priority to CN202411908014.3A priority patent/CN119700965A/zh
Priority to BR112021018727A priority patent/BR112021018727A2/pt
Priority to MX2021011137A priority patent/MX2021011137A/es
Priority to SG11202109822X priority patent/SG11202109822XA/en
Priority to AU2020241882A priority patent/AU2020241882A1/en
Priority to PH1/2021/552092A priority patent/PH12021552092A1/en
Priority to IL317899A priority patent/IL317899A/en
Priority to KR1020217033469A priority patent/KR20210141592A/ko
Priority to CN202411908169.7A priority patent/CN119700966A/zh
Priority to EP20718107.4A priority patent/EP3941522A1/en
Priority to JP2021556435A priority patent/JP7695887B2/ja
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to EA202192568A priority patent/EA202192568A1/ru
Priority to CN202080021576.XA priority patent/CN113573733B/zh
Priority to CA3133995A priority patent/CA3133995A1/en
Publication of WO2020191270A1 publication Critical patent/WO2020191270A1/en
Priority to CONC2021/0011648A priority patent/CO2021011648A2/es
Anticipated expiration legal-status Critical
Priority to JP2025094518A priority patent/JP2025131756A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • Interleukin-33 is a ligand for ST2, a toll-like/interleukin-1 receptor super-family member that associates with an accessory protein, IL-1 RAcP (for reviews, see, e.g., Kakkar and Lee, Nature Reviews - Drug Discovery 7(10): 827-840 (2008), Schmitz et al. , Immunity 23:479-490 (2005); Liew et al., Nature Reviews - Immunology 70:103-110 (2010); US 2010/0260770; US 2009/0041718).
  • the stable liquid pharmaceutical formulation comprises: (i) about 15 mg/ml ⁇ 1.5 mg/ml of the antibody; (ii) about 10 mM ⁇ 2 mM acetate; (iii) about 70 mM ⁇ 14 mM arginine hydrochloride (iv) about 5% w/v ⁇ 1% w/v sucrose; and (iv) about 0.08% ⁇ 0.016% w/v polysorbate 80.
  • the formulation comprises no more than 0.7% HMW species after 12 months of storage at 2-8°C, as determined by SE-UPLC.
  • the stable liquid pharmaceutical formulation comprises no more than 2% HMW species after 18 months of storage at 2-8°C, as determined by SE-UPLC.
  • the formulation comprises no more than 1% HMW species after 18 months of storage at 2-8°C, as determined by SE-UPLC.
  • the formulation comprises no more than 0.7% HMW species after 18 months of storage at 2-8°C, as determined by SE-UPLC.
  • the labeling recites subcutaneous administration of the pharmaceutical formulation. In some embodiments, the labeling recites intravenous administration of the pharmaceutical formulation.
  • antibody is generally intended to refer to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter connected by disulfide bonds, as well as multimers thereof (e.g., IgM); however, immunoglobulin molecules consisting of only heavy chains (i.e., lacking light chains) are also encompassed within the definition of the term "antibody.”
  • Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region comprises three domains, CH1 , CH2 and CH3.
  • the antibodies of the invention may, in some embodiments, be recombinant human antibodies.
  • the term "recombinant human antibody,” as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res.
  • the pharmaceutical formulations contain from 15 ⁇ 0.15 mg/ml to 150 ⁇ 1.5 mg/ml of the anti-IL-33 antibody. In some cases, the pharmaceutical formulations contain 75 mg/mL ⁇ 3.75 mg/mL of the anti-IL-33 antibody. In some cases, the pharmaceutical
  • two antibodies are bioequivalent if there are no clinically meaningful differences in their safety, purity, and potency.
  • two antibodies are bioequivalent if a patient can be switched one or more times between the reference product and the biological product without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or diminished effectiveness, as compared to continued therapy without such switching.
  • the pharmaceutical formulations of the present invention may comprise about 0.5%; about 1.0%; about 1.5%; about 2.0%; about 2.5%; about 3.0%; about 3.5%; about 4.0%; about 4.5%; about 5.0%; about 5.5%; about 6.0%; about 6.5%; about 7.0%; about 7.5%; about 8.0%; about 8.5%; about 9.0%; about 9.5%; about 10.0%; about 15%; or about 20% sugar (e.g., sucrose).
  • sugar e.g., sucrose
  • the formulations contain about 5% sugar (e.g., sucrose).
  • the stable liquid pharmaceutical formulation comprises (i) a human antibody that specifically binds to hlL-33 (e.g ., mAb1) at a concentration of from about 1 mg/ml to about 200 mg/ml; (ii) a buffer (e.g., acetate) at a concentration of from about 1 mM to about 20 mM; (iii) an amino acid (e.g., arginine) at a concentration of from about 30 mM to about 110 mM; (iv) a thermal stabilizer (e.g., sucrose) at a concentration of from about 1 % w/v to about 10% w/v; and (v) an organic cosolvent (e.g., polysorbate 80) at a concentration of from about 0.01 % w/v to about 0.15% w/v.
  • a human antibody that specifically binds to hlL-33 e.g ., mAb1
  • a buffer e.g.,
  • the stable liquid pharmaceutical formulation comprises (i) a human antibody that specifically binds to hlL-33 (e.g., mAb1) at a concentration of from about 15 mg/ml to about 150 mg/ml; (ii) a buffer (e.g., acetate) at a concentration of from about 5 mM to about 15 mM; (iii) an amino acid (e.g., arginine) at a concentration of from about 50 mM to about 90 mM; (iv) a thermal stabilizer (e.g., sucrose) at a concentration of from about 3% w/v to about 7% w/v; and (v) an organic cosolvent (e.g., polysorbate 80) at a concentration of from about 0.05% w/v to about 0.11 % w/v.
  • a human antibody that specifically binds to hlL-33 e.g., mAb1
  • a buffer e.g., acetate
  • the stable liquid pharmaceutical formulation comprises (i) a human antibody that specifically binds to hlL-33 and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20 at a concentration of from about 15 mg/ml to about 150 mg/ml; (ii) acetate at a concentration of about 10 mM; (iii) arginine (e.g., arginine hydrochloride) at a concentration of about 70 mM; (iv) sucrose at a concentration of about 5% w/v; and (v) polysorbate 80 at a concentration of about 0.08% w/v.
  • a human antibody that specifically binds to hlL-33 and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20 at a concentration of from about 15 mg/ml to about 150 mg/ml; (ii
  • a pharmaceutical formulation may also be deemed stable if after three months of storage at -20°C, -30°C, or -80°C less than about 2%, 1.9%, 1.8%, 1.7%, 1.6%, 1.5%, 1 %, 0.5%, or 0.1 % of the antibody is detected in an aggregated form.
  • a low level of viscosity in reference to a fluid formulation of the present invention, will exhibit an absolute viscosity of less than about 20 cPoise (cP) at 20°C.
  • a fluid formulation of the invention will be deemed to have "low viscosity,” if, when measured using standard viscosity measurement techniques, the formulation exhibits an absolute viscosity of about 19 cP, about 18 cP, about 17 cP, about 16 cP, about 15 cP, about 14 cP, about 13 cP, about 12 cP, about 11 cP, about 10 cP, about 9 cP, about 8 cP, about 7 cP, about 6 cP, about 5 cP, about 4 cP, or less.
  • the rubber plungers used in syringes, and the rubber stoppers used to close the openings of vials may be coated to prevent contamination of the medicinal contents of the syringe or vial and/or to preserve their stability.
  • pharmaceutical formulations of the present invention may be contained within a syringe that comprises a coated plunger, or within a vial that is sealed with a coated rubber stopper.
  • the plunger or stopper may be coated with a fluorocarbon film. Examples of coated stoppers and/or plungers suitable for use with vials and syringes containing the pharmaceutical formulations of the present invention are mentioned in, e.g., U.S. Patent Nos.
  • the present invention also includes methods of preparing a unit dosage form.
  • a method for preparing a pharmaceutical unit dosage form includes combining the formulation of any of foregoing embodiments in a suitable container ⁇ e.g., those containers discussed herein).
  • CEX Cation exchange
  • DS Drug substance
  • HMW High molecular weight
  • iCIEF Imaging capillary isoelectric focusing
  • LMW Low molecular weight
  • MCE-SDS Microchip capillary electrophoresis-sodium dodecyl sulfate
  • NR Not required
  • OD Optical density
  • RH Relative humidity
  • RP Reverse phase
  • Table 25 Research Stability of 150 mg/mL mAb1 Drug Product in glass vials Stored at Accelerated and Stress Conditions, and against Agitation
  • CEX Cation exchange
  • DS Drug substance
  • FDG Formulation Development group
  • HMW High molecular weight
  • iCIEF Imaged capillary isoelectric focusing
  • LMW Low molecular weight

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PCT/US2020/023795 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies Ceased WO2020191270A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
EP20718107.4A EP3941522A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies
BR112021018727A BR112021018727A2 (pt) 2019-03-21 2020-03-20 Formulações estabilizadas que contêm anticorpos anti il 33
MX2021011137A MX2021011137A (es) 2019-03-21 2020-03-20 Formulaciones estabilizadas que contienen anticuerpos anti-il-33.
SG11202109822X SG11202109822XA (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies
AU2020241882A AU2020241882A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-iL-33 antibodies
PH1/2021/552092A PH12021552092A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies
IL317899A IL317899A (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies
KR1020217033469A KR20210141592A (ko) 2019-03-21 2020-03-20 항-il-33 항체를 함유하는 안정화된 제형
CN202411908169.7A CN119700966A (zh) 2019-03-21 2020-03-20 含有抗il-33抗体的稳定调配物
IL286024A IL286024B2 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies
CN202411908014.3A CN119700965A (zh) 2019-03-21 2020-03-20 含有抗il-33抗体的稳定调配物
JP2021556435A JP7695887B2 (ja) 2019-03-21 2020-03-20 抗ｉｌ－３３抗体を含有する安定化製剤
EA202192568A EA202192568A1 (ru) 2019-03-21 2020-03-20 Стабилизированные составы, содержащие антитела к il-33
CN202080021576.XA CN113573733B (zh) 2019-03-21 2020-03-20 含有抗il-33抗体的稳定调配物
CA3133995A CA3133995A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies
CONC2021/0011648A CO2021011648A2 (es) 2019-03-21 2021-09-02 Formulaciones estabilizadas que contienen anticuerpos anti-il-33
JP2025094518A JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21
US62/821,661 2019-03-21

Publications (1)

Publication Number Publication Date
WO2020191270A1 true WO2020191270A1 (en) 2020-09-24

Family

ID=70228884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/023795 Ceased WO2020191270A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies

Country Status (19)

Country Link
US (2) US11596690B2 (https=)
EP (1) EP3941522A1 (https=)
JP (2) JP7695887B2 (https=)
KR (1) KR20210141592A (https=)
CN (3) CN119700966A (https=)
AU (1) AU2020241882A1 (https=)
BR (1) BR112021018727A2 (https=)
CA (1) CA3133995A1 (https=)
CL (1) CL2021002440A1 (https=)
CO (1) CO2021011648A2 (https=)
EA (1) EA202192568A1 (https=)
IL (2) IL286024B2 (https=)
MA (1) MA55362A (https=)
MX (1) MX2021011137A (https=)
PH (1) PH12021552092A1 (https=)
SA (1) SA521430229B1 (https=)
SG (1) SG11202109822XA (https=)
TW (2) TW202519263A (https=)
WO (1) WO2020191270A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149521A1 (en) * 2020-05-11 2023-03-22 MedImmune Limited Formulations of anti-il-33 antibodies
US12351626B2 (en) 2021-09-03 2025-07-08 Qyuns Therapeutics Co., Ltd. Anti-human interleukin-33 monoclonal antibody and use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂
WO2023077685A1 (zh) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂
WO2026067832A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-33单域抗体及其衍生物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997423A (en) 1986-10-15 1991-03-05 Daikyo Gomu Seiko Ltd. Laminated sliding stopper for a syringe
US5908686A (en) 1992-01-23 1999-06-01 Daikyo Gomu Seiko, Ltd Modified polysiloxane composition and a sanitary rubber article coated with the composition
US6286699B1 (en) 1995-04-05 2001-09-11 Daikyo Seiko, Ltd. Laminated rubber stopper
US6645635B2 (en) 2001-01-19 2003-11-11 Daikyo Seiko, Ltd. Laminated rubber stopper for a medicament vial
US7226554B2 (en) 1999-01-29 2007-06-05 Daikyo Seiko, Ltd. Molding die assembly for rubber members and rubber member produced thereby
US20090041718A1 (en) 2004-02-17 2009-02-12 Schering Corporation Methods of Modulating Cytokine Activity; Related Reagents
US20100260770A1 (en) 2007-05-18 2010-10-14 Medimmune, Llc Il-33 in inflammatory disease
WO2014164959A2 (en) 2013-03-13 2014-10-09 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
WO2017062456A2 (en) * 2015-10-06 2017-04-13 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0600351D0 (en) 2006-01-10 2006-02-15 Weston Terence E Safe hypodermic needle
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
BR112013008366B1 (pt) * 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
EP2768858B1 (en) * 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PL2892927T3 (pl) * 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
KR20180106974A (ko) 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
WO2020227515A1 (en) * 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997423A (en) 1986-10-15 1991-03-05 Daikyo Gomu Seiko Ltd. Laminated sliding stopper for a syringe
US5908686A (en) 1992-01-23 1999-06-01 Daikyo Gomu Seiko, Ltd Modified polysiloxane composition and a sanitary rubber article coated with the composition
US6286699B1 (en) 1995-04-05 2001-09-11 Daikyo Seiko, Ltd. Laminated rubber stopper
US7226554B2 (en) 1999-01-29 2007-06-05 Daikyo Seiko, Ltd. Molding die assembly for rubber members and rubber member produced thereby
US6645635B2 (en) 2001-01-19 2003-11-11 Daikyo Seiko, Ltd. Laminated rubber stopper for a medicament vial
US20090041718A1 (en) 2004-02-17 2009-02-12 Schering Corporation Methods of Modulating Cytokine Activity; Related Reagents
US20100260770A1 (en) 2007-05-18 2010-10-14 Medimmune, Llc Il-33 in inflammatory disease
WO2014164959A2 (en) 2013-03-13 2014-10-09 Regeneron Pharmaceuticals, Inc. Anti-il-33 antibodies and uses thereof
WO2017062456A2 (en) * 2015-10-06 2017-04-13 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DAUGHERTY A L ET AL: "Formulation and delivery issues for monoclonal antibody therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 686 - 706, XP024892149, ISSN: 0169-409X, [retrieved on 20060807], DOI: 10.1016/J.ADDR.2006.03.011 *
J KANG ET AL: "Rapid Formulation Development for Monoclonal Antibodies - BioProcess InternationalBioProcess International", 12 April 2016 (2016-04-12), XP055349129, Retrieved from the Internet <URL:http://www.bioprocessintl.com/manufacturing/formulation/rapid-formulation-development-for-monoclonal-antibodies/> [retrieved on 20170223] *
KAKKARLEE, NATURE REVIEWS - DRUG DISCOVERY, vol. 7, no. 10, 2008, pages 827 - 840
LIEW ET AL., NATURE REVIEWS - IMMUNOLOGY, vol. 10, 2010, pages 103 - 110
ROBINSON, N.: "Protein Deamidation", PNAS, vol. 99, no. 8, 16 April 2002 (2002-04-16), pages 5283 - 5288
SCHMITZ ET AL., IMMUNITY, vol. 23, 2005, pages 479 - 490
See also references of EP3941522A1
TAYLOR ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295
WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1 - 26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149521A1 (en) * 2020-05-11 2023-03-22 MedImmune Limited Formulations of anti-il-33 antibodies
US12351626B2 (en) 2021-09-03 2025-07-08 Qyuns Therapeutics Co., Ltd. Anti-human interleukin-33 monoclonal antibody and use thereof

Also Published As

Publication number Publication date
AU2020241882A1 (en) 2021-10-14
TWI861073B (zh) 2024-11-11
IL286024B1 (en) 2025-01-01
IL286024B2 (en) 2025-05-01
MX2021011137A (es) 2021-10-22
CN113573733B (zh) 2024-12-31
SG11202109822XA (en) 2021-10-28
JP7695887B2 (ja) 2025-06-19
US20200297845A1 (en) 2020-09-24
TW202519263A (zh) 2025-05-16
EA202192568A1 (ru) 2021-12-03
IL317899A (en) 2025-02-01
US20230346929A1 (en) 2023-11-02
PH12021552092A1 (en) 2022-05-30
CN113573733A (zh) 2021-10-29
EP3941522A1 (en) 2022-01-26
KR20210141592A (ko) 2021-11-23
CL2021002440A1 (es) 2022-04-22
IL286024A (en) 2021-10-31
US11596690B2 (en) 2023-03-07
MA55362A (fr) 2022-01-26
CN119700965A (zh) 2025-03-28
CO2021011648A2 (es) 2021-09-30
JP2022526292A (ja) 2022-05-24
CN119700966A (zh) 2025-03-28
BR112021018727A2 (pt) 2022-02-15
SA521430229B1 (ar) 2024-01-23
CA3133995A1 (en) 2020-09-24
JP2025131756A (ja) 2025-09-09
TW202102260A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
US12077593B2 (en) Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
JP6456470B2 (ja) 抗ｐｃｓｋ９抗体を含む安定化製剤
US20230346929A1 (en) Stabilized Formulations Containing Anti-IL-33 Antibodies
WO2023215267A1 (en) Anti-interleukin-4 receptor (il-4r) antibody formulations
WO2022010988A1 (en) Stabilized formulations containing anti-ctla-4 antibodies
EA045976B1 (ru) Стабилизированные составы, содержащие антитела к il-33
OA19780A (en) Stabilized formulations containing antiinterleukin-6 receptor (IL-6R) antibodies.
EA042167B1 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)
OA16466A (en) Stabilized formulations containing antiinterleukin-6 receptor (IL-6R) antibodies.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20718107

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: NC2021/0011648

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2021000548

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 3133995

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021556435

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021018727

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: NC2021/0011648

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2020241882

Country of ref document: AU

Date of ref document: 20200320

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217033469

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2020718107

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2020718107

Country of ref document: EP

Effective date: 20211021

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021018727

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE US 62/821,661 DE 21/03/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA (NUMERO DE PEDIDO, DATA DO DEPOSITO, PAIS DE ORIGEM, TITULAR E INVENTOR), CONFORME O ART. 15 DA PORTARIA 39/2021, UMA VEZ QUE ESSA INFORMACAO E NECESSARIA PARA O EXAME.

ENP Entry into the national phase

Ref document number: 112021018727

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210920

WWE Wipo information: entry into national phase

Ref document number: 523451433

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 521430229

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 202080021576.X

Country of ref document: CN

WWD Wipo information: divisional of initial pct application

Ref document number: 819259

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 523451433

Country of ref document: SA